UNITED LAB: Class 1 innovative drug UBT251 injection has completed Phase Ia clinical trials in healthy Chinese subjects
United Lab's wholly-owned subsidiary, Federal Biotechnology, has completed Phase I clinical trials of the first-class innovative drug UBT251 injection in healthy subjects in China. The study results show that UBT251 injection has good safety and tolerability in healthy subjects, as well as linear pharmacokinetic characteristics. The study supports once-weekly injection dosing. Subjects experienced a significant weight loss after administration, showing a clear advantage over the placebo group
According to the news from Zhitong Finance and Economics APP, UNITED LAB (03933) announced that its wholly-owned subsidiary, Federal Biotechnology (Zhuhai Hengqin) Co., Ltd., has completed the Phase Ia clinical study of innovative drug UBT251 injection independently developed in China in healthy subjects. This study adopted a randomized, double-blind, placebo-controlled, dose-escalation trial design to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of a single subcutaneous injection of UBT251 in healthy subjects.
The results of this study showed that the safety and tolerability of each dose group after a single dose were good, with no cases of erythema, no serious adverse events, and common adverse reactions being mild to moderate appetite loss and gastrointestinal-related adverse events. Within the dose range of 1.0~4.5mg, the increase in UBT251 exposure was consistent with the increase in dose, showing linear pharmacokinetic characteristics, with an average half-life of 137~170 hours in each dose group, supporting once-weekly dosing. Within the dose range of 1.0~4.5mg, subjects showed a significant decrease in body weight compared to baseline, with an average maximum decrease (Emax) ranging from -3.19 to -4.80kg, significantly better than the placebo group